Coronavirus (COVID-19) News

Found 2,541 articles

• 

  The Rise, Fall and Future of Novavax

  3/21/2023

  On Feb. 28, Novavax issued a candid warning to investors: it may not be able to continue operations beyond February 2024. BioSpace takes a deep dive into the vaccine maker's prospects.

• First-of-Its-Kind Post-COVID-19 Panels Available at questhealth.com

  3/21/2023

  The consumer-initiated testing business from the leader in diagnostic testing, Quest Diagnostics, has introduced two innovative Post-COVID-19 panels.

• Pregnancy Outcomes with COVID-19 Vaccines Reviewed in Journal of American Physicians and Surgeons (AAPS)

  3/21/2023

  The COVID-19 vaccine was developed and distributed with unprecedented speed, including to pregnant women.

• Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia

  3/21/2023

  Jiangsu Recbio Technology Co., Ltd. is pleased to announce that in accordance with the Mongolian law on the prevention of novel coronavirus outbreak, the Company was granted an Emergency Use Authorization for its two-component recombinant COVID-19 vaccine ReCOV by Order No. A106 of the Minister of Public Health of Mongolia and a resolution of the Mongolian Committee for Medicinal Products for Human Use.

• SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic Viruses

  3/20/2023

  SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.

• ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19

  3/13/2023

  ExeVir Bio announced the publication of a pre-print paper by De Cae et al., entitled “Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike”.

• Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies

  3/6/2023

  Invivyd, Inc., a clinical stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announces the election of VYD222 to advance into the clinic as a novel monoclonal antibody therapeutic option for COVID-19.

• Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19

  3/2/2023

  Biophytis SA announced that it has signed a master service agreement with the pharmaceutical company Intsel Chimos, which will become its Pharmaceutical Operator/Exploitant in France for Sarconeos in the context of the early access program application, requested for the treatment of severe forms of COVID-19, if approved.

• Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19

  3/2/2023

  Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of two articles in peer-reviewed scientific journals.

• Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19

  2/27/2023

  Biophytis SA, announced that it has begun the process of early access application in France from the French National Authority for Health for the treatment of severe COVID-19 with Sarconeos.

• FDA Authorizes First Over-the-Counter At-Home Test to Detect Both Influenza and COVID-19 Viruses

  2/24/2023

  The U.S. Food and Drug Administration issued an emergency use authorization for the first over-the-counter at-home diagnostic test that can differentiate and detect influenza A and B, commonly known as the flu, and SARS-CoV-2, the virus that causes COVID-19.

• Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update

  2/21/2023

  Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, provided an update on progress of its Phase 2 KINFAST trial of KIN001 in Covid-19.

• Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma

  2/20/2023

  WestVac Biopharma Co., Ltd. has made significant progress on the development of the trivalent recombinant protein COVID-19 vaccine against the latest prevalent subvariants including XBB.1.5 and BA.5, which is one of the first trivalent recombinant protein vaccines targeting XBB.1.5 worldwide.

• Can the Lingering Effects of a Mild Case of COVID-19 Change Your Brain

  2/20/2023

  People with long COVID who experience anxiety and depression months after a mild case of COVID-19 may have brain changes that affect the function and structure of the brain, according to a preliminary study released February 20, 2023, that will be presented at the American Academy of Neurology's 75th Annual Meeting being held in person in Boston and live online from April 22-27, 2023.

• Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)

  2/17/2023

  Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 in children and adolescents 6 to 17 years of age.

• AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”

  2/17/2023

  AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — announced it will participate in an event hosted by Solve M.E.

• Tonix Pharmaceuticals to Participate in Event Titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”

  2/16/2023

  Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at a virtual event co-hosted by BIO and Solve M.E.

• New Data Links Modulation of Key Immune-Related Proteins to Improvement of Specific Symptoms in Long COVID

  2/16/2023

  Data from a new clinical study show modulation of key immune regulating proteins with maraviroc and pravastatin correlates with symptom reduction in patients with post-acute sequelae of COVID, commonly known as long COVID.

• Therma Bright Secures Exclusive License Agreement for AI4LYF's Patent-Pending Digital Cough Technology (DCT) to Detect Respiratory Diseases

  2/16/2023

  Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies

• Ginkgo Bioworks Announces Pathogen Monitoring Program at Kigali International Airport

  2/15/2023

  Ginkgo Bioworks and the Rwanda Biomedical Centre announced a one-year pathogen monitoring program at Rwanda's Kigali International Airport to identify new and emerging variants of SARS-CoV-2.